Andy Scharenberg, Umoja Biopharma CEO
January 4, 2024 11:16 AM EST
Deals
Cell/Gene Tx

Ab­b­Vie taps Umo­ja for new in vi­vo CAR-T deal

Lei Lei Wu

News Reporter

Ab­b­Vie penned two deals with Umo­ja Bio­phar­ma for its in vi­vo CAR-T cell ther­a­py pro­grams, the com­pa­nies an­nounced Thurs­day.

Ab­b­Vie gets …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

Will CRISPR mat­ter?

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times